Expert Interview 1: Frequently Asked Questions (FAQs) for Non-Muscle-Invasive Bladder Cancer (NMIBC)

Release date: 26-11-2023

Expiration date: 26-11-2024

About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and/or chemotherapy is based on the risk of cancer progression or recurrence.

For practicing oncologists, it is crucial to address Frequently Asked Questions (FAQs) regarding NMIBC such as how to define individual risk groups and treatment recommendations for each group, how to identify BCG refractoriness and relapse in clinical practice, and how to manage patients who are BCG refractory.

Let's watch the recorded video on 'Frequently Asked Questions (FAQs) for NMIBC' to gain comprehensive insights from leading experts – Dr. Francisco X. Real from National Cancer Research Center of Spain and Dr. Félix Guerrero Ramos from Hospital Universitario 12 de Octubre in Madrid, Spain.

This program is available with subtitles in the following languages:

This image has an empty alt attribute; its file name is Screenshot-2023-05-10-144115.png


Francisco X. Real 教授

Francisco X. Real 教授



Francisco X. Real(Paco),MD,PhD自2004年起任西班牙巴塞罗那庞贝大学法布拉分校细胞生物学教授,2007年起也在西班牙马德里西班牙国家癌症研究中心(CNIO)工作。他于1980年在巴塞罗那大学获得MD学位,于1986年获得PhD学位。1986年至1988年在纽约纪念医院接受肿瘤内科培训,并担任内科医师。他在纪念斯隆-凯特琳癌症中心(MSKCC)的Lloyd J. Old实验室开展了博士和博士后工作。他关注于开发治疗黑色素瘤和上皮癌的免疫学策略。1988年,他加入了巴塞罗那市立医学研究所,在那里他专注于上皮癌的细胞和分子生物学。他还参与了庞培法布拉大学生物医学科学研究所的建立。


Real教授已发表原创性论文300余篇,其论文发表在Nature、Nature Genetics、Nature Cell Biology、Nature Communications、Nature Reviews Cancer、Gut、Gastroenterology、PNAS、JNCI、J Clin Invest、N Engl J Med、Lancet等杂志。他的论文被引用超过29000次(谷歌学术搜索),他的H指数为96。他是多个机构科学咨询委员会的成员,包括英国癌症研究研发委员会(伦敦)、Cordeliers研究中心(巴黎)、CARPEM(巴黎)、英国胰腺癌研究中心(伦敦)和国家科学研究基金会(布鲁塞尔)。他是Gut和Bladder Cancer的副主编。2015年,曾任欧洲胰腺俱乐部主席。

Félix Guerrero 教授

Félix Guerrero 教授

Doce de Octubre医院


Félix Guerrero-Ramos是西班牙马德里12 de Octubre大学医院肿瘤泌尿科的共同负责人,并作为泌尿科医生为患者提供外科手术治疗。他还是12 de Octubre大学医院的住院项目主任,同时也是马德里康普顿斯大学(医学院)最后一年学生的学术导师。此外,Guerrero-Ramos是CEU San Pablo大学的医学副教授。他还同时在马德里HM医院和ROC诊所兼任肿瘤泌尿科主任。

Guerrero-Ramos于2008年在马德里自治大学获得医学博士学位,随后在12 de Octubre大学医院接受泌尿科医生培训。在住院实习期间,他还在英国伦敦大学学院医院完成了临床见习。2014年6月他在比利时布鲁塞尔的欧洲泌尿外科委员会获得奖学金,并于2015年12月以优异的成绩获得马德里康普顿斯大学的博士学位。他的博士论文题目是“在常温保存下非对照的DCD肾脏捐献项目中手术并发症的比较分析”。


This activity is design designed for medical oncologists and urologists involved or interested in the management of urothelial cancer.

The aim of this educational activity is for participants to:


  • Define individual risk groups for non-muscle-invasive bladder cancer (NMIBC)
  • Appreciate the current and evolving treatment options for NMIBC
  • Identify BCG refractoriness and relapse and develop treatment plan for BCG refractory patients

This educational activity is provided by ACE Oncology.

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.

This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:


Félix Guerrero has served as an advisor or consultant for Pfizer, BMS, AstraZeneca, Janssen and Combat Medical. He has also served as a speaker or a member of a speakers bureau for Astellas Oncology, Janssen, Pfizer, AstraZeneca, Combat Medical and Nucleix. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


Francisco X. Real has received grants for research from VCN Biosciences and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.


The employees of ACE Oncology have disclosed no relevant financial relationships.


ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.